Recce Pharmaceuticals Ltd is a cutting-edge biotech company that is leading the charge in developing and bringing to market a new class of synthetic antibiotics that are designed to combat the growing problem of antibiotic-resistant superbugs. The company has developed an automated process to manufacture its lead compound, which has been validated ahead of the first-in-human clinical trials. With its groundbreaking technology, Recce Pharmaceuticals is poised to make a major impact on global public health.